FBIONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as FBIOP
Fortress Biotech, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.87+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $59.45M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.83 (−30.74%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Fortress Biotech, Inc. grew revenue 15.5% to $68.47M over the twelve months to Jun 30, 2026.
Revenue
$68.47M
+15.5% vs. a year earlier
Operating income
-$29.35M
TTM Q2 2026
EPS, diluted
-$0.07
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $59.45M
- P/E ratio
- –
- Price to sales
- 0.87
- Price to book
- 0.36
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $68.47M
- Net income
- $111.82M
- EPS, diluted
- -$0.07
- Book value per share
- $5.16
- Diluted shares
- 32M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$68.47M+15.5% YoY
Gross profit
$44.91M+11.1% YoY
Operating income
-$29.35M
Net income
$111.82M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months